Where Did the Margin Go? Modernizing Pharma’s Financial Supply Chain

For procurement, R&D finance and FP&A, further systematization can’t solve the problem, but next-generation tools for the pharma financial supply chain can.

In pharma, margin leakage rarely shows up as one problem. It shows up in the seams: a vendor change order that was approved outside the core workflow; a trial forecast that no longer matches the operating plan; a rebate accrual that misses the real channel mix; or a chargeback dispute that is discovered after revenue has already been reported. By the time these issues reach the P&L, the damage is often already done.

As therapies become more specialized, R&D becomes more outsourced and commercial channels become more fragmented, the pharma financial supply chain is getting harder to manage, and the challenges will only intensify in the years ahead. For procurement, R&D finance and FP&A, further systematization can’t solve the problem, but next-generation tools for the pharma financial supply chain can.

In this GrowthBit, we’ll look at the specific challenges this supply chain faces and the tools that show early promise in solving them.

The problem is that many of these tools were not built for the operating complexity that pharma teams now face.

Better systems can’t solve margin leakage

Procurement leaders are being asked to control increasingly complex external spend. R&D finance and FP&A teams are being asked to forecast trial costs and operating plans across moving assumptions. Commercial finance and Gross-To-Net (“GTN”) teams are being asked to manage rebates, 340B, government pricing, returns and reimbursement economics across a growing number of contracts and channels.

The growth of specialized therapies is creating even more complexity, fragmentation and system opacity. But the problem is not a lack of systems. Most pharma companies already have ERPs, procurement tools, spreadsheets, data warehouses and reporting dashboards. The problem is that many of these tools were not built for the operating complexity that pharma teams now face. Workflows still break across PDFs, email threads, spreadsheets, disconnected approvals and siloed data. The result is limited visibility into spend, contract logic and net revenue outcomes before they become financial surprises.

That is why the next generation of pharma financial supply chain tools matters. The opportunity is to move from manual reconciliation after the fact to governed execution before leakage reaches the P&L.

Digital procurement programs have been associated with lower off-contract spend, including estimates of 15% to 30% improvement in maverick or off-contract purchasing.

Procurement leaders need to control outsourced spend

Procurement teams sit at the front end of the financial supply chain, helping to determine which vendors are used, how work is scoped, how contracts are approved, how spend is routed and how supplier performance is monitored. In pharma, that role is becoming more important as sponsors rely more heavily on CROs, CDMOs and other external service providers.

But outsourced spending is often highly fragmented and relationship-driven. Vendor discovery, supplier qualification, SOW creation, approval routing, contracting, purchase orders, change orders and ongoing vendor management happen across multiple systems. Even with a formal eProcurement platform, much of the real work may still occur outside the system.

Change orders are one of the clearest examples. A vendor may bid aggressively to win a project, then expand scope and cost through a series of amendments that are difficult to compare, track and govern. For procurement leaders, the issue is not only whether the original price was fair. It is whether the organization can see the full spend trajectory, understand why costs changed, enforce the right approval logic and compare the scope to market or contracted rates.

Promising Tools > Guided buying, eProcurement, and marketplace and vendor management platforms help address this gap. They can standardize requisitions, approvals, SOW governance, vendor onboarding, supplier qualification, compliance documentation, audit status and line-item visibility. Digital procurement programs have been associated with lower off-contract spend, including estimates of 15% to 30% improvement in maverick or off-contract purchasing.¹

Many teams still manage clinical trial workflows through spreadsheets, static budget templates and manual variance analyses that can’t capture this variability.

Clinical FP&A teams need governed trial forecasting

Clinical finance, R&D finance and FP&A teams own a second layer of the financial supply chain: translating trial design and development decisions into an accurate spend forecast. In pharma, that workflow spans protocol design, site activation, enrollment assumptions, patient timelines, CRO and lab budgets, drug supply, manufacturing inputs, amendments and milestone timing.

The challenges of pharmaceutical financial planning are especially acute in clinical trials. Trial budgets are shaped by a multitude of inputs and when any of those assumptions shift, the budget can change materially. Yet many teams still manage these workflows through spreadsheets, static budget templates and manual variance analyses that can’t capture this variability.

Promising Tools > Dedicated FP&A and trial-costing tools can help teams build budgets prospectively based on study design, vendor rates, timelines and operating assumptions, then compare forecasted costs to actuals as the trial progresses. Instead of treating the budget as a static artifact, next-generation planning tools make the budget a live workflow. For the clinical finance teams who need to connect protocol assumptions, vendor budgets, enrollment curves, site activation timelines, amendments, pass-through costs and actual invoices into one governed forecast for the R&D planning cycle, a connected workflow can help them understand what changed, why it changed, who approved it and how the change affects the trial budget, development plan and cash forecast.

As rules, contracts and channel paths multiply, software needs to evolve beyond spreadsheet-based GTN workflows to provide auditability, governance, forecasting and intelligence.

GTN and reimbursement teams need governed channel economics

Led by the office of the CFO, commercial finance, market access, government pricing and GTN teams need better tools to govern financial outcomes. For branded pharma manufacturers, list price is only the starting point. Realized revenue is shaped by rebates, 340B discounts, chargebacks, returns, service fees, government pricing obligations, payer contracts, distributor relationships and channel-specific deductions.

These deductions can be material. Some industry estimates suggest that gross-to-net reductions across large branded-drug portfolios often approximate half of list price, with reported portfolio-level discounts commonly falling in the ~40%–60% range.² As a result, small errors in eligibility logic, rebate accruals, chargeback processing, or duplicate-discount prevention can create significant financial impact.

Channel proliferation makes the problem harder. Specialty distribution, limited networks, direct-to-patient models, value-based agreements and evolving payer dynamics increase the number of contracts, counterparties, and pricing permutations that manufacturers need to govern. Government pricing and 340B add another layer of complexity. Manufacturers need to manage Average Manufacturer Price, Medicaid Best Price, state transparency requirements and HRSA rules prohibiting duplicate discounts involving both a 340B price and a Medicaid rebate for the same drug.³

Promising Tools > As rules, contracts and channel paths multiply, software needs to evolve beyond spreadsheet-based GTN workflows to provide auditability, governance, forecasting and intelligence. Critical metrics include off-contract rate, price variance to contract, accrual accuracy, deduction leakage, dispute recovery, and close-cycle time. But the broader value proposition is governance. GTN platforms help translate complex pricing and reimbursement rules into controlled workflows that finance, commercial, contracting and compliance teams can trust.

The next generation of financial supply chain software will help pharma companies answer these three questions earlier and with more confidence…

The pharma financial supply chain needs cross-domain tools

Procurement, clinical planning and GTN may look like separate domains, but they are increasingly connected. Procurement decisions shape vendor commitments and external spend. Trial and commercial forecasts shape budgets, cash needs and resource allocation. GTN execution determines how much gross revenue turns into realized net revenue. When these workflows are managed in silos, leadership sees the full financial picture too late.

The next generation of financial supply chain software will help pharma companies answer three questions earlier and with more confidence: 1) Where are we committing spend? 2) How will that spend affect the plan? 3) How much revenue will we actually keep?

That requires more than another dashboard. It requires governed workflows, structured contract logic, better system integration and audit-ready data across procurement, planning and GTN execution. It also requires tools built for pharma-specific complexity rather than horizontal systems that need heavy customization to fit regulated, outsourced and channel-heavy operating models.

Here’s the bottom line.

The pharma financial supply chain is moving from manual reconciliation toward governed execution. Procurement leaders need better control over outsourced spend. Clinical FP&A teams need governed trial forecasting that reflects changing protocol, enrollment and vendor assumptions. GTN and reimbursement teams need auditable tools to manage increasingly complex channel economics. Solving these problems involves creating a cross-domain operating layer that helps pharma teams see spend earlier, plan more accurately, govern pricing logic, reduce leakage and protect margins before financial surprises reach the P&L.

Learn more about the LLR team, relevant investment experience and our focus on the Pharma Financial Supply Chain sector.